LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation on behalf of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On May 14, 2020, the U.S. Food and Drug Administration announced that early data "suggest[s] potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19 . . . and [that] the test may return false negative results."
On this news, Abbott's share price fell sharply during intraday trading on May 15, 2020.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased Abbott securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to firstname.lastname@example.org, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.